Amedica Submits Response to FDA for Clearance of Composite Interbody Spinal Device

Amedica (AMDA) submitted its responses to FDA in relation to the CASCADE clinical trial.

CASCADE compared 24-month outcomes from single-level cervical fusion between AMDA's porous silicon nitride vs. autograft bone. Data indicated that porous silicon nitride achieved clinical and radiographic outcomes that were...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us